Inhaled Microplastics Linked To Lung Cancer, Study Finds
“About 66% of lung cancer patients had detectable microplastics found in fluid samples taken from their lungs, compared to 46% of people without lung cancer, researchers reported Sunday at a meeting of the European Respiratory Society in Barcelona, Spain.”
Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial
“Sept 8 (Reuters) – Amgen’s (AMGN.O), opens new tab targeted immunotherapy, Imdelltra, combined with AstraZeneca’s (AZN.L), opens new tab cancer drug Imfinzi, significantly improved overall survival in patients with extensive-stage small-cell lung cancer in a late-stage trial, the companies said on Tuesday.”
$60 Israeli blood test can detect stage 2-4 lung cancer with 93% accuracy, study shows
“Israeli researchers have developed a simple, fast, $60 blood test for diagnosing lung cancer that eliminates the need for costly DNA sequencing. In peer-reviewed research of 103 participants, the test accurately identified 93 percent of stage 2-4 lung cancers while ruling out cancer in 90 percent of the healthy control group. Using fluorescent light, the scientists analyzed chemical patterns on DNA fragments circulating in the bloodstream.”
Groundbreaking Pancreatic Cancer Drug Shows Promise in Lung Cancer
“Key Takeaways: The oral RAS inhibitor daraxonrasib recently received FDA approval for metastatic pancreatic ductal adenocarcinoma. The drug achieved objective responses in more than 30% of patients with metastatic RAS-mutant non-small cell lung cancer in a phase I/II trial. Daraxonrasib also demonstrated promising antitumor activity in docetaxel-naive patients who had previously received first- or second-line platinum-based chemotherapy and anti-PD-(L)1 therapy.”
Akeso, Summit cancer drug confirms lung cancer survival benefit
“A dual-acting cancer drug developed by China-based Akeso helped people with lung cancer live longer after treatment than did Merck & Co.’s blockbuster immunotherapy Keytruda, the company said Thursday, results that support an emerging body of evidence suggesting the medicine may become a future backbone of non-small cell lung cancer care.”
